**(Formerly known as Kapil Cotex Limited)** Skybiotech Healthcare Limited is an Indian listed entity currently executing a fundamental strategic pivot from the textile industry to the pharmaceutical and life sciences sectors. Following a period of stagnant revenue in its legacy business, the company has undergone a formal rebranding (effective **November 7, 2025**) and a major acquisition to establish itself as an integrated healthcare provider. --- ### **Strategic Pivot & Corporate Rebranding** The company is transitioning away from its historical operations in the manufacturing, dyeing, and trading of cotton yarn and fabrics. This shift is necessitated by the fact that the legacy textile business has generated **zero revenue** for over **three years**. To reflect its new identity and industrial focus, the company has implemented the following changes: * **Name Change:** Transitioned from **Kapil Cotex Limited** to **Skybiotech Healthcare Limited**. * **MOA Amendment:** The **Main Object Clause** of the Memorandum of Association has been altered to encompass the entire pharmaceutical value chain, from R&D to global distribution. * **Headquarters Relocation:** The registered office was moved from **Mumbai** to **Chhatrapati Sambhaji Nagar (Aurangabad)**, Maharashtra, to optimize operational efficiency and economic viability. --- ### **Core Subsidiary & Manufacturing Capabilities** The company’s operational entry into the healthcare sector is anchored by its majority stake in a specialized manufacturing subsidiary. | Subsidiary Name | Stake Acquired | Acquisition Date | Investment Value | | :--- | :--- | :--- | :--- | | **Skybiotech Life Sciences Private Limited** | **72.52%** | **July 1, 2024** | **Rs. 10 Crores** | **Acquisition Details:** * **Volume:** **6,880,746 equity shares** purchased at **Rs. 14.50 per share**. * **Operational Focus:** The subsidiary serves as the primary vehicle for manufacturing pharmaceutical products and ingredients. --- ### **Integrated Healthcare Business Model** Skybiotech Healthcare Limited is positioned as a comprehensive healthcare entity. Its updated business model covers four primary segments: * **Pharmaceutical Formulations:** Manufacturing finished dosage forms, including **tablets, capsules, syrups, ointments, injections, and powders** for both human and animal healthcare. * **Bulk Drugs & APIs:** Production of **Active Pharmaceutical Ingredients (APIs)** and chemical **intermediates** for the global pharmaceutical industry. * **Nutraceuticals:** Development and compounding of specialized nutritional supplements and wellness products. * **Research & Development:** Establishment of **laboratories, R&D centers, and pilot plants** to innovate medicinal products and refine chemical processes. * **Global Trade:** Engaging in the **import, export, and distribution** of healthcare preparations across international markets. **Segmental Overview:** | Segment | Key Activities | Target Markets | | :--- | :--- | :--- | | **Formulations** | Finished dosage manufacturing | Healthcare Providers & Retail | | **Bulk Drugs** | **API** and **Intermediate** production | Pharma Manufacturers | | **R&D & Testing** | Innovation and quality testing | Internal & External Clients | | **Nutraceuticals** | Health and wellness supplements | Preventive Care Market | --- ### **Financial Performance & Capital Structure** The company is currently in a "gestation" phase of its transition, reflected in its standalone and consolidated financials. **Standalone Financial Summary (Transition Period):** | Metric | FY 2024-25 | FY 2023-24 | | :--- | :--- | :--- | | **Total Revenue** | **Rs. 18.12 Lakhs** | **Rs. 200.23 Lakhs** | | **Net Profit / (Loss)** | **(Rs. 28.73 Lakhs)** | **Rs. 70.30 Lakhs** | **Consolidated Performance (Including Subsidiary):** For the nine-month period ending **December 31, 2024**, the consolidated entity reported: * **Total Revenue:** **Rs. 6.22 Crore** * **Net Loss After Tax:** **Rs. (154.36) Lakhs** **Capital Raising & Investment Limits:** To fund its inorganic growth strategy, the company has significantly expanded its financial capacity: * **Authorized Share Capital:** Increased from **Rs. 2.00 Crores** to **Rs. 5.00 Crores**. * **Investment/Loan Limit (u/s 186):** Shareholders have been asked to approve a new limit of **Rs. 100 Crores** to facilitate future acquisitions. * **Preferential Allotment (2024):** Issued **9,60,000 shares** at **Rs. 76.30 per share**, raising approximately **Rs. 7.32 Crores** for working capital. --- ### **Operational Infrastructure & Governance** * **Segment Reporting:** The company currently operates under a **single reportable segment**; therefore, separate reporting under **AS 17** is not yet applicable. * **Internal Controls:** The **Accounts Department** monitors compliance, while the **Internal Audit** function reports directly to the **Audit Committee**. * **Cost Records:** Maintenance of cost records under **Section 148** was not applicable for **FY 2024-25**. * **Accounting Standards:** Financials are prepared in accordance with **Indian Accounting Standards (Ind AS)** and **Section 133** of the Companies Act, 2013. --- ### **Risk Factors & Regulatory Compliance** The company faces several hurdles related to its rapid transition and historical compliance lapses. **1. Regulatory & Statutory Challenges:** The company has identified several instances of non-compliance with the **Companies Act, 2013**: * **Section 186 (2) Violation:** The **Rs. 10 Crore** investment in Skybiotech Life Sciences exceeded statutory limits without a prior **Special Resolution**. Management is seeking post-facto ratification. * **Filing Lapses:** Failure to file **Form MGT-14** for acquisitions and **Form DIR-12** for Director/KMP appointments within mandatory timelines. * **Board Composition:** The **Nomination and Remuneration Committee (NRC)** was non-compliant with **Section 178 (1)**; the company is currently appointing a third Non-Executive Director to rectify this. * **KMP Turnover:** High instability in the Compliance Officer role, with two resignations within one fiscal year. **2. Industry & Market Risks:** * **Digital Disruption:** The need to pivot toward **online sales channels** as traditional retail footfall declines. * **Rising Costs:** Increasing labor costs necessitate investments in **automation** to protect margins. * **Global Competition:** Entry of giants like **Amazon** into the fashion/healthcare retail space. * **Geographic Exposure:** Management maintains a cautious stance on the **US market** due to high retail insolvency rates in 2024. **Compliance Summary Table:** | Statutory Provision | Nature of Non-Compliance | Status | | :--- | :--- | :--- | | **Section 186 (2)** | Investment exceeded legal limits | Seeking member ratification | | **Section 178 (1)** | **NRC** composition lacked majority | Appointment in progress | | **Section 117 (3)** | Failure to file **Form MGT-14** | Outstanding | | **Section 161 (1)** | Failure to file **Form DIR-12** | Director resigned Aug 2025 | --- ### **Future Growth Drivers** * **Inorganic Expansion:** Leveraging the **Rs. 100 Crore** investment limit to acquire further pharmaceutical assets. * **Export Incentives:** Utilizing increased **MEIS rates (from 2% to 4%)** to target non-traditional markets in **South America, Russia, and West Asia**. * **R&D Focus:** Transitioning from a trading-heavy model to a high-margin **innovation-led** pharmaceutical manufacturer.